Dr. Reddy's Laboratories Announces the Launch of Bupropion HCl Extended-Release Tablets, USP (SR) in the U.S. Market
September 02 2016 - 11:32AM
Business Wire
Dr. Reddy’s Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE:
RDY) announced today that it has launched Bupropion HCl
extended-release tablets, USP (SR) in 100 mg, 150 mg and 200 mg, a
therapeutic equivalent generic version of Wellbutrin® SR (bupropion
HCl) Sustained-Release Tablets in the United States market approved
by the U.S. Food & Drug Administration (USFDA).
The Wellbutrin® SR brand and generic had U.S. sales of
approximately $109.6 million MAT for the most recent twelve months
ending in July 2016 according to IMS Health*.
Dr. Reddy’s Buproprion SR tablets are available in 100 mg, 150
mg and 200 mg, in bottle count sizes of 60, 100 and 500.
Wellbutrin® SR is a registered trademark of the GSK group of
companies.
*IMS National Sales Perspective: Retail and Non-Retail MAT July
2016RDY-0716-128
About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE:
500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical
company, committed to providing affordable and innovative medicines
for healthier lives. Through its three businesses - Pharmaceutical
Services & Active Ingredients, Global Generics and Proprietary
Products – Dr. Reddy’s offers a portfolio of products and services
including APIs, custom pharmaceutical services, generics,
biosimilars and differentiated formulations. Our major therapeutic
areas of focus are gastrointestinal, cardiovascular, diabetology,
oncology, pain management and dermatology. Dr. Reddy’s operates in
markets across the globe. Our major markets include – USA, India,
Russia & CIS countries, and Europe. For more information, log
on to: www.drreddys.com
Disclaimer: This press release may include statements of
future expectations and other forward-looking statements that are
based on the management’s current views and assumptions and involve
known or unknown risks and uncertainties that could cause actual
results, performance or events to differ materially from those
expressed or implied in such statements. In addition to statements
which are forward-looking by reason of context, the words "may",
"will", "should", "expects", "plans", "intends", "anticipates",
"believes", "estimates", "predicts", "potential", or "continue" and
similar expressions identify forward-looking statements. Actual
results, performance or events may differ materially from those in
such statements due to without limitation, (i) general economic
conditions such as performance of financial markets, credit
defaults , currency exchange rates , interest rates , persistency
levels and frequency / severity of insured loss events (ii)
mortality and morbidity levels and trends, (iii) changing levels of
competition and general competitive factors, (iv) changes in laws
and regulations and in the policies of central banks and/or
governments, (v) the impact of acquisitions or reorganization ,
including related integration issues.
The company assumes no obligation to update any information
contained herein.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160902005495/en/
Dr. Reddy's Laboratories Ltd.Investor
RelationsSaunak Savla,
+91-40-49002135saunaks@drreddys.comorMedia RelationsCalvin
Printer, +91-40-49002121)calvinprinter@drreddys.com
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
From Feb 2024 to Mar 2024
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
From Mar 2023 to Mar 2024